CPX 351: A THERAPEUTIC CHALLANGE IN SECONDARY ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE

被引：0
|
作者：
Piccioni, A. L. [1 ]
Cedrone, M. [1 ]
Ceresoli, E. [1 ]
Anaclerico, B. [1 ]
Borza, P. Anticoli [1 ]
Bongarzoni, V. [1 ]
Fenu, S. [1 ]
Finolezzi, E. [1 ]
Crescenzi, S. Leonetti [1 ]
Tamburini, A. [1 ]
Cudillo, L. [1 ]
机构：
[1] UOC Ematol Azienda Ospedaliera S Giovanni Addolor, Rome, Italy
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
D061
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [1] CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia
    Talati, Chetasi
    Lancet, Jeffrey E.
    FUTURE ONCOLOGY, 2018, 14 (12) : 1147 - 1154
  • [2] CPX-351 TREATMENT IN SECONDARY ACUTE MYELOID LEUKEMIA (SAML): THE REAL LIFE EXPERIENCE FROM THE "ITALIAN TRIVENETO REGISTRY"
    Fili, C.
    Candoni, A.
    Mauro, E.
    Scattolin, A. M.
    Leoncin, M.
    Gurrieri, C.
    Nadali, G.
    Mosna, F.
    Michieli, M. G.
    Lico, A.
    Lazzarotto, D.
    Zannier, M. E.
    Simeone, E.
    Facchin, G.
    Battaglia, G.
    Gherlinzoni, F.
    Bassan, R.
    Semenzato, G.
    Fanin, R.
    HAEMATOLOGICA, 2021, 106 (10) : 128 - 129
  • [3] Efficacy and Safety Profile of CPX-351 in Secondary Acute Myeloid Leukemia (sAML): A Systematic Review
    Ibrahim, Ahmed
    Yousaf, Muhammad Abdullah
    Ikram, Mariam
    Khalid, Huma
    Anum
    Safdar, Omar A.
    Anwer, Zain
    Faraz, Fatima
    Rehman, Mohammad
    Saad, Muhammad
    BLOOD, 2023, 142
  • [4] Real-world experience with CPX-351 in high-risk acute myeloid leukemia
    Lemoli, Roberto M.
    Montesinos, Pau
    Jain, Akriti
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 185
  • [5] CPX-351 in FLT3-mutated acute myeloid leukemia
    Andrews, Claire
    Pullarkat, Vinod
    Recher, Christian
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
    Ronson, Aaron
    Tvito, Ariella
    Rowe, Jacob M.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (04): : 369 - 374
  • [7] Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia
    Przespolewski, Amanda
    Goldberg, Aaron D.
    Talati, Chetasi
    Fazal, Salman
    Vachhani, Pankit
    Sanikommu, Srinivasa R.
    Thota, Swapna
    Waksal, Julian
    Ball, Brian
    Famulare, Christopher
    Stahl, Maximilian
    Baron, Jeffrey
    Griffiths, Elizabeth A.
    Thompson, James E.
    Sweet, Kendra
    Wang, Eunice S.
    BLOOD, 2023, 141 (12) : 1489 - 1493
  • [8] Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
    Chen, Evan C.
    Fathi, Amir T.
    Brunner, Andrew M.
    ONCOTARGETS AND THERAPY, 2018, 11 : 3425 - 3434
  • [9] Secondary acute myeloid leukemia - a single center experience
    Szotkowski, T.
    Rohon, P.
    Zapletalova, J.
    Sicova, K.
    Hubacek, J.
    Indrak, K.
    NEOPLASMA, 2010, 57 (02) : 170 - 178
  • [10] CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia
    Lee, Dasom
    Jain, Akriti G.
    Deutsch, Yehuda
    Eatrides, Jennifer
    Chan, Onyee
    Padron, Eric
    Kuykendall, Andrew
    Komrokji, Rami
    Lancet, Jeffrey
    Sallman, David
    Talati, Chetasi
    Sweet, Kendra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (10): : 774 - 779
12345